Can a diabetes drug protect dialysis Patients' hearts?

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion criteria: * Hemodialysis for more than 3 months (5 also with residual diuresis) * Age ≥18 years of age * Willing to sign informed consent Exclusion criteria: * Mentally incapacitated subjects (i.e. not able to sign informed consent) * Subjects who participated in a trial with exposure to radiation before, are only allowed to participate if the total cumulative radiation burden in their life does not exceed 1 mSv per year, counting from the age of 18 years. * Pregnant women and women of child-bearing potential who are not using reliable contraception * Subjects on diuretics are allowed to participate but the dose should be stable for at least 4 weeks prior to screening * Subjects already on a SGLT2 inhibitor are allowed to participate, but the drug should be inter-rupted 1 week prior to the first study day till the end of the second study day (as the half-life is 10-13 hours a wash-out of the study drug of at least 7-days should be considered) * History of hypersensitivity to canagliflozin or another SGLT2 inhibitor * Severe claustrophobia * History of drug or alcohol abuse within the 12 months prior to dosing, or evidence of such abuse as indicated by the laboratory assays conducted during the screening. * Any medication, surgical or medical condition which might significantly alter the absorption, distribution, metabolism, or excretion of medications including, but not limited to any of the following: * Major gastrointestinal tract surgery such as gastrectomy, gastroenterostomy, or bowel resection * Gastro-intestinal ulcers and/or gastrointestinal or rectal bleeding within last six months * Pancreatic injury or pancreatitis within the last six months * Evidence of hepatic disease as determined by any one of the following: ALT or AST values exceeding 3x ULN at inclusion visit, a history of hepatic encephalopathy, a history of esophageal varices, or a history of portocaval shunt * Use of rifampicin and cholestryramine * Established peripheral arterial disease * Active cardiovascular disease: myocardial infarction, angina pectoris, percutaneous translu-minal coronary angioplasty, coronary artery bypass grafting, stroke, or heart failure (NYHA I-IV) admission \< 3 months before inclusion * People using digoxin and/or lithium * Patients with an active malignancy